Treatment and prevention of bone complications from prostate cancer, Bone, vol.48, issue.1, pp.88-95, 2011. ,
DOI : 10.1016/j.bone.2010.05.038
Practical guide to bone health in the spectrum of advanced prostate cancer, Can J Urol. 2014, vol.21, issue.2, pp.84-92 ,
Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer, Asian Journal of Andrology, vol.16, issue.3, p.341, 2014. ,
DOI : 10.4103/1008-682X.122591
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. Clin Cancer Res, pp.6243-6249, 2006. ,
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013. ,
DOI : 10.1056/NEJMoa1213755
Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy, Urology, vol.67, issue.1, pp.152-157, 2006. ,
DOI : 10.1016/j.urology.2005.07.017
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer, Annals of Oncology, vol.16, issue.4, pp.579-84, 2005. ,
DOI : 10.1093/annonc/mdi122
Effects of skeletal morbidities on longitudinal patient-?reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer, pp.869-76, 2007. ,
Burden of skeletal-?related events in prostate cancer: unmet need in pain improvement. Support Care Cancer, pp.237-284, 2015. ,
Male Osteoporosis in the Elderly, Int J Endocrinol, vol.2015, pp.1-8, 2015. ,
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures, Osteoporosis International, vol.16, issue.suppl 2, pp.1726-1759, 2006. ,
DOI : 10.1007/s00198-006-0172-4
Study on the distribution features of bone metastases in prostate cancer, Nuclear Medicine Communications, vol.33, issue.4 ,
DOI : 10.1097/MNM.0b013e3283504528
Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.8, pp.3656-61, 2002. ,
DOI : 10.1210/jcem.87.8.8782
A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk, Journal of Bone and Mineral Research, vol.359, issue.6, pp.893-902, 2004. ,
DOI : 10.1359/JBMR.040134
Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer, Annals of Oncology, vol.24, issue.1, pp.31-39, 2013. ,
DOI : 10.1093/annonc/mds216
Platinum-?Based Chemotherapy for Variant Castrate-?Resistant Prostate Cancer. Clin Cancer Res, pp.3621-3651, 2013. ,
DOI : 10.1158/1078-0432.ccr-12-3791
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699964
Quality Assurance Guidelines for Percutaneous Vertebroplasty, CardioVascular and Interventional Radiology, vol.18, issue.1, pp.173-181, 2006. ,
DOI : 10.1007/s00270-005-0146-5
Acute vertebral collapse: CT findings in benign and malignant nontraumatic cases., Radiology, vol.194, issue.1, pp.41-49, 1995. ,
DOI : 10.1148/radiology.194.1.7997579
Acute vertebral collapse due to osteoporosis or malignancy: appearance on unenhanced and gadolinium-enhanced MR images., Radiology, vol.199, issue.2, pp.541-550, 1996. ,
DOI : 10.1148/radiology.199.2.8668809
Vertebral compression fractures: distinction between benign and malignant causes with MR imaging., Radiology, vol.172, issue.1, 1989. ,
DOI : 10.1148/radiology.172.1.2740506
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatology, vol.39, issue.12, pp.215-223, 2000. ,
DOI : 10.1093/rheumatology/39.12.1383
Bone health in cancer patients: ESMO Clinical Practice Guidelines, Annals of Oncology, vol.25, issue.suppl 3, pp.124-161, 2014. ,
DOI : 10.1093/annonc/mdu103
Risk of Fracture after Androgen Deprivation for Prostate Cancer, New England Journal of Medicine, vol.352, issue.2, pp.154-64, 2005. ,
DOI : 10.1056/NEJMoa041943
Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men, The Journal of Urology, vol.184, issue.3, pp.918-941, 2010. ,
DOI : 10.1016/j.juro.2010.04.068
Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.31, pp.7897-903, 2005. ,
DOI : 10.1200/JCO.2004.00.6908
Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC), ASCO Annu Meet, 2013. ,
Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease, Best Practice & Research Clinical Endocrinology & Metabolism, vol.17, issue.4, pp.575-89, 2003. ,
DOI : 10.1016/S1521-690X(03)00053-8
Management of cancer treatment-induced bone loss, Nature Reviews Rheumatology, vol.22, issue.6 ,
DOI : 10.1038/nrrheum.2013.36
Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer, Urology, vol.69, issue.3, pp.500-504, 2007. ,
DOI : 10.1016/j.urology.2006.11.002
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, Journal of Clinical Oncology, vol.26, issue.2, pp.242-247, 2008. ,
DOI : 10.1200/JCO.2007.12.4008
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-?resistant prostate cancer progressing after docetaxel treatment: a randomised open-?label trial, Lancet, 2010. ,
Abiraterone and Increased Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.364, issue.21, pp.1995-2005, 2011. ,
DOI : 10.1056/NEJMoa1014618
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, The Lancet Oncology, vol.16, issue.2, pp.152-60, 2015. ,
DOI : 10.1016/S1470-2045(14)71205-7
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer, European Urology, vol.70, issue.3, 2016. ,
DOI : 10.1016/j.eururo.2016.02.035
Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer, JNCI Journal of the National Cancer Institute, vol.96, issue.11, pp.879-82, 2004. ,
DOI : 10.1093/jnci/djh141
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-?resistant prostate cancer: a randomised, double-?blind study. The Lancet Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-?Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance), EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-?Resistant Prostate Cancer, pp.813-835, 2011. ,
Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review, The Oncologist, vol.17, issue.9, pp.1171-1180, 2012. ,
DOI : 10.1634/theoncologist.2012-0051
Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy, Management of decreased bone mineral density in men starting androgen-?deprivation therapy for prostate cancer ,
DOI : 10.2147/CMAR.S74116
Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study, Bone, vol.34, issue.1, pp.195-202, 2004. ,
DOI : 10.1016/j.bone.2003.10.001
FRAX TM and the assessment of fracture probability in men and women from the UK. Osteoporos Int, pp.385-97, 2008. ,
Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer, BJU International, vol.133, issue.6, pp.776-785, 2005. ,
DOI : 10.1016/S0090-4295(99)00061-8
Dose de tolérance à l'irradiation des tissus sains : l'os chez l'adulte. Cancer/Radiothérapie, pp.386-91, 2010. ,
Bone Health and Pelvic Radiotherapy, Clinical Oncology, vol.27, issue.11, p.2015 ,
DOI : 10.1016/j.clon.2015.07.006
Vertebral fractures ??? An underestimated side-effect in patients treated with radio(chemo)therapy, Radiotherapy and Oncology, vol.118, issue.3, 2016. ,
DOI : 10.1016/j.radonc.2016.02.021
Pelvic fractures following irradiation of endometrial and vaginal cancers???a case series and review of literature, Radiotherapy and Oncology, vol.56, issue.1, pp.23-31, 2000. ,
DOI : 10.1016/S0167-8140(00)00178-X
Micro-CT Analysis of Radiation-Induced Osteopenia and Bone Hypovascularization in Rat, Calcified Tissue International, vol.170, issue.3, 2015. ,
DOI : 10.1007/s00223-015-0010-9
A murine model for bone loss from therapeutic and space-relevant sources of radiation, Journal of Applied Physiology, vol.101, issue.3, pp.789-93, 1985. ,
DOI : 10.1152/japplphysiol.01078.2005
Insufficiency Fractures After Pelvic Radiotherapy in Patients With Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.77, issue.3, pp.818-841, 2010. ,
DOI : 10.1016/j.ijrobp.2009.05.059
Aggressive Variants of Castration-?Resistant Prostate Cancer. Clin Cancer Res, pp.2846-50, 2014. ,
Projection de l???incidence et de la mortalit?? par cancer urologique en France en 2012, VI. BIBLIOGRAPHIE 1. International Agency for Research on Cancer. GLOBOACAN 2012, pp.57-65, 2013. ,
DOI : 10.1016/S1166-7087(13)70047-2
Diagnosis, treatment, follow up of urological cancers], CCAFU Recommendations Prog En Urol J Assoc Fr Urol Société Fr Urol, vol.2013, 2013. ,
A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy, BJU International, vol.349, issue.11, pp.1627-1662, 2012. ,
DOI : 10.1111/j.1464-410X.2011.10584.x
Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC), European Urology, vol.62, issue.5, pp.745-52, 2012. ,
DOI : 10.1016/j.eururo.2012.05.068
Early Detection of Prostate Cancer: European Association of Urology Recommendation, European Urology, vol.64, issue.3, pp.347-54, 2013. ,
DOI : 10.1016/j.eururo.2013.06.051
Long-?term biochemical disease-?free and cancer-? specific survival following anatomic radical retropubic prostatectomy. The 15-?year Johns Hopkins experience ,
DOI : 10.1016/s0094-0143(05)70163-4
Natural History of Progression After PSA Elevation Following Radical Prostatectomy, JAMA, vol.281, issue.17, pp.1591-1598, 1999. ,
DOI : 10.1001/jama.281.17.1591
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, pp.1228-1270, 2005. ,
DOI : 10.1097/01.pas.0000173646.99337.b1
Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores, European Urology, vol.61, issue.3, pp.480-487, 2012. ,
DOI : 10.1016/j.eururo.2011.10.044
The prognostic significance of perineural invasion in prostatic cancer biopsies, Cancer, vol.97, issue.1, pp.13-24, 2007. ,
DOI : 10.1002/cncr.22388
Positive Surgical Margins in Radical Prostatectomy: Outlining the Problem and Its Long-Term Consequences, European Urology, vol.55, issue.1, pp.87-99, 2009. ,
DOI : 10.1016/j.eururo.2008.09.051
Diffusion-weighted Endorectal MR Imaging at 3 T for Prostate Cancer: Tumor Detection and Assessment of Aggressiveness, Radiology, vol.259, issue.3, pp.775-84, 2011. ,
DOI : 10.1148/radiol.11102066
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM, Annals of Surgical Oncology, vol.17, issue.6, pp.1471-1475, 2010. ,
DOI : 10.1245/s10434-010-0985-4
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer, JAMA, vol.280, issue.11, pp.969-74, 1998. ,
DOI : 10.1001/jama.280.11.969
Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System V, on behalf of the ESMO Guidelines Working Group Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-?up, International Society of Urological Pathology Am J Surg Pathol. Feb Ann Oncol, vol.4024, issue.2 6, pp.244-52, 2013. ,
The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis, European Urology, vol.64, issue.1, pp.106-123 ,
DOI : 10.1016/j.eururo.2013.04.019
Mise au point??: TEP-choline et cancer de la prostate, Progr??s en Urologie, vol.24, issue.1, pp.3-8 ,
DOI : 10.1016/j.purol.2013.07.016
Studies on prostatic cancer, Cancer Res, vol.1, p.297, 1941. ,
Update on Hsp90 Inhibitors in Clinical Trial, Current Topics in Medicinal Chemistry, vol.9, issue.15, pp.1479-92, 2009. ,
DOI : 10.2174/156802609789895728
Androgen insensitivity syndrome. The Lancet, pp.1419-1447, 2012. ,
Androgen receptors in hormone-dependent and castration-resistant prostate cancer, Pharmacology & Therapeutics, vol.140, issue.3, pp.223-261, 2013. ,
DOI : 10.1016/j.pharmthera.2013.07.003
Molecular Biology of the Androgen Receptor, Journal of Clinical Oncology, vol.20, issue.13, pp.3001-3016, 2002. ,
DOI : 10.1200/JCO.2002.10.018
Mechanisms of resistance in castration-?resistant prostate cancer (CRPC), Transl Androl Urol, vol.4, issue.3, pp.365-80, 2015. ,
The development of androgen-independent prostate cancer, Nature Reviews Cancer, vol.1, issue.1, pp.34-45, 2001. ,
DOI : 10.1038/35094009
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-?ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell, pp.443-54, 2010. ,
The importance of non-?nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cell Signal, pp.348-56, 2016. ,
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer, New England Journal of Medicine, vol.371, issue.11, pp.1028-1066, 2014. ,
DOI : 10.1056/NEJMoa1315815
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201502
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer, Cancer Research, vol.69, issue.1, pp.16-22, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-2764
Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer, Molecular Cancer Therapeutics, vol.14, issue.1, pp.59-69, 2015. ,
DOI : 10.1158/1535-7163.MCT-14-0521
Le traitement hormonal du cancer de la prostate, Progr??s en Urologie, vol.23, issue.15, pp.1246-57, 2013. ,
DOI : 10.1016/j.purol.2013.08.325
Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers. Clin Cancer Res, pp.4072-4081, 2006. ,
Receptor affinity and potency of non-?steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis, 1998. ,
Development of a Second-?Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science, pp.787-90, 2009. ,
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion, Nat Clin Pract Urol, 2009. ,
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, Journal of Clinical Oncology, vol.26, issue.7, pp.1148-59, 2008. ,
DOI : 10.1200/JCO.2007.12.4487
Molecular determinants of resistance to antiandrogen therapy, Nature Medicine, vol.10, issue.1, pp.33-42, 2004. ,
DOI : 10.1038/nm972
Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex, Endocrine Reviews, vol.28, issue.7, pp.778-808, 2007. ,
DOI : 10.1210/er.2007-0019
Radical Prostatectomy versus Observation for Localized Prostate Cancer Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med N Engl J Med, vol.367364, issue.4318, pp.203-131708, 2011. ,
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, The Lancet, vol.373, issue.9660, pp.301-309, 2009. ,
DOI : 10.1016/S0140-6736(08)61815-2
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial, The Lancet, vol.378, issue.9809, pp.2104-2115, 2012. ,
DOI : 10.1016/S0140-6736(11)61095-7
Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer, Journal of Clinical Oncology, vol.26, issue.15, pp.2497-504, 2008. ,
DOI : 10.1200/JCO.2007.14.9021
Duration of Androgen Suppression in the Treatment of Prostate Cancer, New England Journal of Medicine, vol.360, issue.24, pp.2516-2543, 2009. ,
DOI : 10.1056/NEJMoa0810095
URL : https://hal.archives-ouvertes.fr/hal-00492521
Natural History of Biochemical Recurrence after Radical Prostatectomy: Risk Assessment for Secondary Therapy, European Urology, vol.51, issue.5, pp.1175-84, 2007. ,
DOI : 10.1016/j.eururo.2007.01.015
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference, International Journal of Radiation Oncology*Biology*Physics, vol.65, issue.4, pp.965-74, 2006. ,
DOI : 10.1016/j.ijrobp.2006.04.029
Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy, JAMA, vol.291, issue.11, pp.1325-1357, 2004. ,
DOI : 10.1001/jama.291.11.1325
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group, N Engl J Med Br J Urol Feb, vol.36779, issue.102, pp.895-903, 1997. ,
Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma, British Journal of Urology, vol.35, issue.5, pp.502-510, 1991. ,
DOI : 10.1111/j.1464-410X.1991.tb15195.x
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial, Urology, vol.46, issue.2, pp.220-226, 1995. ,
DOI : 10.1016/S0090-4295(99)80197-6
Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer, Annals of Internal Medicine, vol.132, issue.7, pp.566-77, 2000. ,
DOI : 10.7326/0003-4819-132-7-200004040-00009
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, The Lancet, vol.355, issue.9214, pp.1491-1499, 2000. ,
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer, New England Journal of Medicine, vol.368, issue.14, pp.1314-1339, 2013. ,
DOI : 10.1056/NEJMoa1212299
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, New England Journal of Medicine, vol.373, issue.8, pp.737-783, 2015. ,
DOI : 10.1056/NEJMoa1503747
Addition of docetaxel, zoledronic acid, or both to first-?line long-?term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet Androgen-?deprivation therapy alone or with docetaxel in non-?castrate metastatic prostate cancer (GETUG-?AFU 15): a randomised, pp.open-?label, 2015. ,
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, The Lancet Oncology, vol.17, issue.2, pp.243-56, 2016. ,
DOI : 10.1016/S1470-2045(15)00489-1
Characterising the castration-resistant prostate cancer population: a systematic review, International Journal of Clinical Practice, vol.13, issue.A615, pp.1180-92, 2011. ,
DOI : 10.1111/j.1742-1241.2011.02799.x
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, Journal of Clinical Oncology, vol.26, issue.2, pp.242-247, 2008. ,
DOI : 10.1200/JCO.2007.12.4008
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. 65 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, vol.351, issue.15, pp.1513-1533, 2004. ,
DOI : 10.1056/nejmoa040720
Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer, JNCI Journal of the National Cancer Institute, vol.96, issue.11, pp.879-82, 2004. ,
DOI : 10.1093/jnci/djh141
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial, Journal of Clinical Oncology, vol.27, issue.32, pp.5431-5439, 2009. ,
DOI : 10.1200/JCO.2008.20.1228
Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC), ASCO Annu Meet, 2013. ,
EAU guidelines on prostate cancer European Urology Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts, J Urol, vol.71169, issue.5, pp.1729-1763, 2003. ,
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-?resistant prostate cancer progressing after docetaxel treatment: a randomised open-?label trial, Lancet, 2010. ,
Abiraterone and Increased Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.364, issue.21, pp.1995-2005, 2011. ,
DOI : 10.1056/NEJMoa1014618
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, The Lancet Oncology, vol.16, issue.2, pp.152-60, 2015. ,
DOI : 10.1016/S1470-2045(14)71205-7
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012. ,
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014. ,
DOI : 10.1056/NEJMoa1405095
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931
Cabazitaxel vs docetaxel in chemotherapy-?naive (CN) patients with metastatic castration-?resistant prostate cancer (mCRPC): A three-?arm phase III study (FIRSTANA) Sipuleucel-?T immunotherapy for castration-?resistant prostate cancer, J Clin Oncol N Engl J Med, vol.34363, issue.5, pp.2016411-2016433, 2010. ,
Radiopharmaceuticals for the palliation of painful bone metastasis-?a systemic review, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.75, issue.3, pp.258-70, 2005. ,
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013. ,
DOI : 10.1056/NEJMoa1213755
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial, The Lancet Oncology, vol.15, issue.12, pp.1397-406, 2014. ,
DOI : 10.1016/S1470-2045(14)70474-7
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France., Journal of Clinical Oncology, vol.33, issue.7_suppl, pp.1471-2407222, 2015. ,
DOI : 10.1200/jco.2015.33.7_suppl.264
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies, European Urology, vol.68, issue.2, pp.228-263, 2015. ,
DOI : 10.1016/j.eururo.2014.04.015
Antitumour activity of abiraterone acetate against metastatic castration-?resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol, pp.1807-1819, 2013. ,
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment, Cancer, vol.72, issue.15 suppl, pp.968-753391, 2014. ,
DOI : 10.1002/cncr.28518
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1, Journal of Clinical Oncology, vol.34, issue.25, pp.3005-3018, 2016. ,
DOI : 10.1200/JCO.2015.65.5597
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)., Journal of Clinical Oncology, vol.33, issue.7_suppl, p.2015 ,
DOI : 10.1200/jco.2015.33.7_suppl.141
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-?resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-?043): a multicentre, randomised, double-?blind, phase 3 trial, Lancet Oncol, vol.8915, issue.7, pp.700-712, 2014. ,
CA184-?095: A randomized, double-?blind, phase III trial to compare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-?naive castration-?resistant prostate cancer (CRPC), J Clin Oncol, vol.30, p.2012 ,
Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks, European Urology, vol.55, issue.1, pp.62-75, 2009. ,
DOI : 10.1016/j.eururo.2008.10.008
A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer, European Urology, vol.67, issue.4, pp.673-682 ,
DOI : 10.1016/j.eururo.2014.10.004
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, The Lancet, vol.377, issue.9768, pp.813-835, 2011. ,
DOI : 10.1016/S0140-6736(10)62344-6
Study on the distribution features of bone metastases in prostate cancer, Nuclear Medicine Communications, vol.33, issue.4, pp.379-83 ,
DOI : 10.1097/MNM.0b013e3283504528
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. Clin Cancer Res, pp.6243-6249, 2006. ,
Undertreatment of Osteoporosis in Men With Hip Fracture, Archives of Internal Medicine, vol.162, issue.19, pp.2217-2239, 2002. ,
DOI : 10.1001/archinte.162.19.2217
The near absence of osteoporosis treatment in older men with fractures, Osteoporosis International, vol.161, issue.8, pp.953-62, 2005. ,
DOI : 10.1007/s00198-005-1950-0
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures, Osteoporosis International, vol.16, issue.suppl 2, pp.1726-1759, 2006. ,
DOI : 10.1007/s00198-006-0172-4
Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men, Annals of Internal Medicine, vol.152, issue.6, pp.380-90, 2010. ,
DOI : 10.7326/0003-4819-152-6-201003160-00008
Metastatic bone disease: clinical features, pathophysiology and treatment strategies, Cancer Treatment Reviews, vol.27, issue.3, 2001. ,
DOI : 10.1053/ctrv.2000.0210
Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy, Urology, vol.67, issue.1, pp.152-157, 2006. ,
DOI : 10.1016/j.urology.2005.07.017
Risk of Fracture after Androgen Deprivation for Prostate Cancer, New England Journal of Medicine, vol.352, issue.2, pp.154-64, 2005. ,
DOI : 10.1056/NEJMoa041943
Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.8, pp.3656-61, 2002. ,
DOI : 10.1210/jcem.87.8.8782
Management of cancer treatment-induced bone loss, Nature Reviews Rheumatology, vol.22, issue.6, pp.365-74 ,
DOI : 10.1038/nrrheum.2013.36
Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer, Annals of Oncology, vol.24, issue.1, pp.31-39, 2013. ,
DOI : 10.1093/annonc/mds216
Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease, Best Practice & Research Clinical Endocrinology & Metabolism, vol.17, issue.4, pp.575-89, 2003. ,
DOI : 10.1016/S1521-690X(03)00053-8
Bone health in cancer patients: ESMO Clinical Practice Guidelines, Annals of Oncology, vol.25, issue.suppl 3, pp.124-161, 2014. ,
DOI : 10.1093/annonc/mdu103
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.12, 2005. ,
DOI : 10.1210/jc.2005-0183
Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer, Urology, vol.57, issue.1, pp.127-159, 2001. ,
DOI : 10.1016/S0090-4295(00)00895-5
Practical guide to bone health in the spectrum of advanced prostate cancer ,
Androgen deprivation therapy for prostate cancer: new concepts and concerns, Current Opinion in Endocrinology, Diabetes and Obesity, vol.14, issue.3, pp.247-54, 2007. ,
DOI : 10.1097/MED.0b013e32814db88c
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047388
Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men, The Journal of Urology, vol.184, issue.3, pp.918-941, 2010. ,
DOI : 10.1016/j.juro.2010.04.068
Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.31, pp.7897-903, 2005. ,
DOI : 10.1200/JCO.2004.00.6908
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer, Annals of Oncology, vol.16, issue.4, pp.579-84, 2005. ,
DOI : 10.1093/annonc/mdi122
Effects of skeletal morbidities on longitudinal patient-?reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer, pp.869-76, 2007. ,
Burden of skeletal-?related events in prostate cancer: unmet need in pain improvement. Support Care Cancer, pp.237-284, 2015. ,
Osteoporosis in the European Union: medical management, epidemiology and economic burden, Archives of Osteoporosis, vol.8, issue.1-2, pp.1-2, 2013. ,
DOI : 10.1007/s11657-013-0136-1
1007/s11657-?013-?0136-?1 Economic Impacts of Skeletal-?Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. The Oncologist, pp.320-326, 2016. ,
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer, European Urology, vol.68, issue.1 ,
DOI : 10.1016/j.eururo.2014.10.001
Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer, Current Opinion in Oncology, vol.26, issue.3, pp.274-83, 2014. ,
DOI : 10.1097/CCO.0000000000000071
Bone Marrow, Cytokines, and Bone Remodeling ??? Emerging Insights into the Pathophysiology of Osteoporosis, New England Journal of Medicine, vol.332, issue.5, pp.305-316, 1995. ,
DOI : 10.1056/NEJM199502023320506
Bone Quality ??? The Material and Structural Basis of Bone Strength and Fragility, New England Journal of Medicine, vol.354, issue.21, pp.2250-61, 2006. ,
DOI : 10.1056/NEJMra053077
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, Cell, vol.93, issue.2, pp.165-76, 1998. ,
DOI : 10.1016/S0092-8674(00)81569-X
URL : http://doi.org/10.1016/s0092-8674(00)81569-x
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proceedings of the National Academy of Sciences, vol.95, issue.7, pp.3597-602, 1998. ,
DOI : 10.1073/pnas.95.7.3597
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-?node organogenesis, Nature, vol.397, issue.6717, pp.315-338, 1999. ,
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-328, 1997. ,
DOI : 10.1016/S0092-8674(00)80209-3
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro, Endocrinology, vol.139, issue.3, pp.1329-1366, 1998. ,
DOI : 10.1210/en.139.3.1329
A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms, Molecular and Cellular Endocrinology, vol.310, issue.1-2, pp.1-221, 2009. ,
DOI : 10.1016/j.mce.2009.04.004
URL : https://hal.archives-ouvertes.fr/hal-00512215
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity, Journal of Cellular Biochemistry, vol.86, issue.1 ,
DOI : 10.1002/jcb.10662
Managing bone metastases and reducing skeletal related events in prostate cancer, Nature Reviews Clinical Oncology, vol.65, issue.6, pp.335-380, 2014. ,
DOI : 10.1002/jbmr.1613
The effect of porosity and mineral content on the Young's modulus of elasticity of compact bone, Journal of Biomechanics, vol.21, issue.2, pp.131-140, 1988. ,
DOI : 10.1016/0021-9290(88)90006-1
Age-dependent change in the 3D structure of cortical porosity at the human femoral midshaft, Bone, vol.40, issue.4, pp.957-65, 2007. ,
DOI : 10.1016/j.bone.2006.11.011
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men, Journal of Clinical Investigation, vol.106, issue.12, pp.1553-60, 2000. ,
DOI : 10.1172/JCI10942
Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.1, pp.204-214, 2003. ,
DOI : 10.1210/jc.2002-021036
The influence of age on bone mineral regulating hormones, Bone, vol.7, issue.6, pp.421-426, 1986. ,
DOI : 10.1016/8756-3282(86)90001-3
Relationship between circulating insulin-?like growth factor components and sex hormones in a population-?based sample of 50-? to 80-?year-?old men and women, J Clin Endocrinol Metab, vol.81, issue.7, pp.2534-2574, 1996. ,
Insulin-Like Growth Factor I Is a Determinant of Hip Bone Mineral Density in Men Less Than 60 years of Age: MINOS Study, Calcified Tissue International, vol.76, issue.4, 2004. ,
DOI : 10.1007/s00223-003-0090-9
Osteoporosis in men, Nature Reviews Endocrinology, vol.21, issue.11, pp.637-682, 2013. ,
DOI : 10.1038/nrendo.2013.171
Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice Available from, Open Orthop J, vol.3, issue.1, 2009. ,
Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages, Current Pharmaceutical Design, vol.16, issue.27, pp.2950-60, 2010. ,
DOI : 10.2174/138161210793563635
The effects of alendronate on bone turnover and bone quality, Int J Clin Pract, vol.101, pp.14-21, 1999. ,
Denosumab in patients with cancer???a surgical strike against the osteoclast, Nature Reviews Clinical Oncology, vol.11, issue.2 ,
DOI : 10.1038/nrclinonc.2011.197
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women, Journal of Bone and Mineral Research, vol.273, issue.7, pp.1059-66, 2004. ,
DOI : 10.1359/JBMR.040305
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates, Journal of Clinical Oncology, vol.27, issue.10, pp.1564-71, 2009. ,
DOI : 10.1200/JCO.2008.19.2146
Quality Assurance Guidelines for Percutaneous Vertebroplasty, CardioVascular and Interventional Radiology, vol.18, issue.1, pp.173-181, 2006. ,
DOI : 10.1007/s00270-005-0146-5
What Proportion of Incident Radiographic Vertebral Deformities Is Clinically Diagnosed and Vice Versa? J Bone Miner Res, pp.1216-1238, 2005. ,
Timing of Subsequent Fractures after an Initial Fracture, Current Osteoporosis Reports, vol.92, issue.3, pp.118-140, 2010. ,
DOI : 10.1007/s11914-010-0023-2
Fracture risk following an osteoporotic fracture, Osteoporosis International, vol.15, issue.3, pp.175-184, 2004. ,
DOI : 10.1007/s00198-003-1514-0
Surgical Management of Spinal Metastases, The Oncologist, vol.9, issue.2, pp.188-96, 2004. ,
DOI : 10.1634/theoncologist.9-2-188
Prevalence of thoracolumbar vertebral fractures on multidetector CT, European Journal of Radiology, vol.69, issue.3, 2009. ,
DOI : 10.1016/j.ejrad.2007.11.036
Under-reporting of osteoporotic vertebral fractures on computed tomography, European Journal of Radiology, vol.69, issue.1, pp.179-83, 2009. ,
DOI : 10.1016/j.ejrad.2007.08.028
Vertebral fracture assessment using a semiquantitative technique, Journal of Bone and Mineral Research, vol.13, issue.S1, pp.1137-1185, 1993. ,
DOI : 10.1002/jbmr.5650080915
Diagnostic d'un tassement vertébral non traumatique récent, Imagerie ostéo-?articulaire, pp.1293-310, 1998. ,
Acute vertebral collapse: CT findings in benign and malignant nontraumatic cases., Radiology, vol.194, issue.1, pp.41-49, 1995. ,
DOI : 10.1148/radiology.194.1.7997579
Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol, pp.1017-1044, 2007. ,
MRI of Spinal Bone Marrow: Part 2, T1-Weighted Imaging-Based Differential Diagnosis, American Journal of Roentgenology, vol.197, issue.6, pp.1309-1330, 2011. ,
DOI : 10.2214/AJR.11.7420
Acute vertebral collapse due to osteoporosis or malignancy: appearance on unenhanced and gadolinium-enhanced MR images., Radiology, vol.199, issue.2, pp.541-550, 1996. ,
DOI : 10.1148/radiology.199.2.8668809
Vertebral compression fractures: distinction between benign and malignant causes with MR imaging., Radiology, vol.172, issue.1, pp.215-223, 1989. ,
DOI : 10.1148/radiology.172.1.2740506
Diffusion-weighted MR imaging of bone marrow: differentiation of benign versus pathologic compression fractures., Radiology, vol.207, issue.2, pp.349-56, 1998. ,
DOI : 10.1148/radiology.207.2.9577479
The utility of in-?phase/opposed-?phase imaging in differentiating malignancy from acute benign compression fractures of the spine, Am J Neuroradiol, vol.27, issue.6, pp.1183-1191, 2006. ,
Routine needle biopsy during vertebral augmentation procedures. Is it necessary? Eur Spine J, pp.1894-1902, 2010. ,
DOI : 10.1007/s00586-010-1388-8
Computed Tomography and Magnetic Resonance Imaging in the Differentiation of Osteoporotic Fractures From Neoplastic Metastatic Fractures, Journal of Clinical Densitometry, vol.19, issue.1, 2015. ,
DOI : 10.1016/j.jocd.2015.08.008
A family history of fracture and fracture risk: a meta-analysis, Bone, vol.35, issue.5, pp.1029-1066, 2004. ,
DOI : 10.1016/j.bone.2004.06.017
A meta-analysis of previous fracture and subsequent fracture risk, Bone, vol.35, issue.2, pp.375-82, 2004. ,
DOI : 10.1016/j.bone.2004.03.024
Body mass index as a predictor of fracture risk: A meta-analysis, Osteoporosis International, vol.14, issue.11, pp.1330-1338, 2005. ,
DOI : 10.1007/s00198-005-1863-y
Smoking and fracture risk: a meta-analysis, Osteoporosis International, vol.15, issue.2, pp.155-62, 2005. ,
DOI : 10.1007/s00198-004-1640-3
Alcohol intake as a risk factor for fracture, Osteoporosis International, vol.13, issue.7, pp.737-779, 2005. ,
DOI : 10.1007/s00198-004-1734-y
Screening older cancer patients: first evaluation of the G-8 geriatric screening tool, Annals of Oncology, vol.23, issue.8, pp.2166-72, 2012. ,
DOI : 10.1093/annonc/mdr587
Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer, Journal of Clinical Oncology, vol.30, issue.15, pp.1829-1863, 2012. ,
DOI : 10.1200/JCO.2011.35.7442
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, BMJ, vol.312, issue.7041, pp.1254-1263, 1996. ,
DOI : 10.1136/bmj.312.7041.1254
Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women, JAMA, vol.286, issue.22, pp.2815-2837, 2001. ,
DOI : 10.1001/jama.286.22.2815
Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study, Bone, vol.34, issue.1, 2004. ,
DOI : 10.1016/j.bone.2003.10.001
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer, European Urology, vol.65, issue.2, pp.467-79, 2014. ,
DOI : 10.1016/j.eururo.2013.11.002
FRAX TM and the assessment of fracture probability in men and women from the UK. Osteoporos Int, pp.385-97, 2008. ,
Cost-effective osteoporosis treatment thresholds: the United States perspective, Osteoporosis International, vol.15, issue.4, pp.437-484, 2008. ,
DOI : 10.1007/s00198-007-0550-6
Case finding for the management of osteoporosis with FRAX®?assessment and intervention thresholds for the UK. Osteoporos Int, pp.1395-408, 2008. ,
Du bon usage du FRAX??, Revue du Rhumatisme, vol.76, issue.1, pp.1-3, 2009. ,
DOI : 10.1016/j.rhum.2008.11.001
Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer, The Journal of Urology, vol.183, issue.6, pp.2200-2205, 2010. ,
DOI : 10.1016/j.juro.2010.02.022
Comparison of Fracture Risk Assessment Tool Score to Bone Mineral Density for Estimating Fracture Risk in Patients With Advanced Prostate Cancer on Androgen Deprivation Therapy, Urology, vol.84, issue.1, pp.164-172, 2014. ,
DOI : 10.1016/j.urology.2013.12.071
Management of osteoporosis in men on androgen deprivation therapy, Maturitas, vol.68, issue.2, 2011. ,
DOI : 10.1016/j.maturitas.2010.11.003
The relationship between daily calcium intake and bone mineral density in men with prostate cancer, BJU International, vol.173, issue.4, pp.812-818, 2007. ,
DOI : 10.1111/j.1464-410X.2006.05885.x
A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention, New England Journal of Medicine, vol.367, issue.1, pp.40-49, 2012. ,
DOI : 10.1056/NEJMoa1109617
Use of Calcium or Calcium in Combination With Vitamin D Supplementation to Prevent Fractures and Bone Loss in People Aged 50 Years and Older: A Meta-analysis, Obstetrical & Gynecological Survey, vol.63, issue.1, pp.657-66, 2007. ,
DOI : 10.1097/01.ogx.0000298339.68546.3c
Calcium supplementation: Balancing the cardiovascular risks, Maturitas, vol.69, issue.4, pp.289-95, 2011. ,
DOI : 10.1016/j.maturitas.2011.04.014
Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review, The Oncologist, vol.17, issue.9, pp.1171-1180, 2012. ,
DOI : 10.1634/theoncologist.2012-0051
Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study, The Journal of Urology, vol.179, issue.1, pp.152-157, 2008. ,
DOI : 10.1016/j.juro.2007.08.137
Raloxifene to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer: A Randomized Controlled Trial, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.8, pp.3841-3847, 2004. ,
DOI : 10.1210/jc.2003-032058
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer, J Urol, 2010. ,
Toremifene Decreases Vertebral Fractures in Men Younger Than 80 Years Receiving Androgen Deprivation Therapy for Prostate Cancer, The Journal of Urology, vol.186, issue.6, pp.2239-2283, 2011. ,
DOI : 10.1016/j.juro.2011.07.090
Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy, Journal of Clinical Oncology, vol.26, issue.27, pp.4426-4460, 2008. ,
DOI : 10.1200/JCO.2007.15.1233
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer, New England Journal of Medicine, vol.345, issue.13, pp.948-55, 2001. ,
DOI : 10.1056/NEJMoa010845
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade, Cancer, vol.88, issue.6, pp.1444-50, 2001. ,
DOI : 10.1002/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M
Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer, Journal of Bone and Mineral Research, vol.69, issue.11, pp.1766-70, 2004. ,
DOI : 10.1359/JBMR.040813
Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer, The Journal of Urology, vol.169, issue.6, pp.2008-2020, 2003. ,
DOI : 10.1097/01.ju.0000063820.94994.95
Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist???Induced Bone Loss in Men With Prostate Cancer, Journal of Clinical Oncology, vol.25, issue.9, pp.1038-1080, 2007. ,
DOI : 10.1200/JCO.2006.07.3361
Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer, The Journal of Urology, vol.176, issue.3, 2006. ,
DOI : 10.1016/j.juro.2006.04.078
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer, New England Journal of Medicine, vol.361, issue.8, pp.745-55, 2009. ,
DOI : 10.1056/NEJMoa0809003
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038121
Practical guidance for the management of aromatase inhibitor-associated bone loss, Annals of Oncology, vol.19, issue.8, pp.1407-1423, 2008. ,
DOI : 10.1093/annonc/mdn164
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, The Lancet, vol.379, issue.9810, pp.39-46, 2012. ,
DOI : 10.1016/S0140-6736(11)61226-9
Placebo-?Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial). CancerSpectrum Knowl Environ, pp.1300-1311, 2003. ,
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials, The Lancet Oncology, vol.10, issue.9, pp.872-878, 2009. ,
DOI : 10.1016/S1470-2045(09)70201-3
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance), Journal of Clinical Oncology, vol.32, issue.11, pp.1143-50, 2014. ,
DOI : 10.1200/JCO.2013.51.6500
Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer, Asian Journal of Andrology, vol.16, issue.3, p.341, 2014. ,
DOI : 10.4103/1008-682X.122591
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events, Annals of Oncology, vol.26, issue.2, pp.368-74 ,
DOI : 10.1093/annonc/mdu519
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma, Journal of Clinical Oncology, vol.29, issue.9, pp.1125-1157, 2011. ,
DOI : 10.1200/JCO.2010.31.3304
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial, The Lancet Oncology, vol.13, issue.12, pp.1210-1217, 2012. ,
DOI : 10.1016/S1470-2045(12)70473-4
Effect of enzalutamide on time to first skeletal-?related event, pain, and quality of life in men with castration-?resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial health-?related quality of life, pain, and skeletal-?related events in asymptomatic and minimally symptomatic, chemotherapy-?naive patients with metastatic castration-?resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial, Lancet Oncol. Lancet Oncol, vol.1516, issue.105, pp.1147-56509, 2014. ,
Treatment of osteoporotic vertebral compression fractures with percutaneous vertebroplasty under local anesthesia: clinical and radiological results, Int J Clin Exp Med, vol.8, issue.9, p.16287, 2015. ,
Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty], Neurochirurgie, vol.33, issue.2, pp.166-174, 1987. ,
Prospective Evaluation of Pain Relief in 100 Patients Undergoing Percutaneous Vertebroplasty: Results and Follow-up, Journal of Vascular and Interventional Radiology, vol.13, issue.9, 2002. ,
DOI : 10.1016/S1051-0443(07)61770-9
Percutaneous Vertebroplasty for Osteoporotic Compression Fractures: Quantitative Prospective Evaluation of Long-term Outcomes, Journal of Vascular and Interventional Radiology, vol.13, issue.2, pp.139-187, 2002. ,
DOI : 10.1016/S1051-0443(07)61930-7
Percutaneous Vertebroplasty: Technical Considerations, Journal of Vascular and Interventional Radiology, vol.14, issue.8, pp.953-60, 2003. ,
DOI : 10.1097/01.RVI.0000083255.29749.A8
Traitement des métastases osseuses par radiologie interventionnelle, Bull Cancer (Paris), vol.96, issue.11, pp.1117-1143, 2009. ,
The clinical efficacy of vertebroplasty on osteoporotic vertebral compression fracture: A meta-analysis, International Journal of Surgery, vol.12, issue.12, pp.1249-53, 2014. ,
DOI : 10.1016/j.ijsu.2014.10.027
A Randomized Trial of Vertebroplasty for Osteoporotic Spinal Fractures, New England Journal of Medicine, vol.361, issue.6, pp.569-79, 2009. ,
DOI : 10.1056/NEJMoa0900563
A Randomized Trial of Vertebroplasty for Painful Osteoporotic Vertebral Fractures, New England Journal of Medicine, vol.361, issue.6, pp.557-68, 2009. ,
DOI : 10.1056/NEJMoa0900429
Have Recent Vertebroplasty Trials Changed the Indications for Vertebroplasty? Cardiovasc Intervent Radiol, pp.677-80, 2010. ,
DOI : 10.1007/s00270-010-9901-3
Complications of percutaneous vertebroplasty and their prevention Available from, Skeletal Radiol [Internet], vol.33, issue.9, pp.256-260, 2004. ,
Fatal pulmonary cement embolism following percutaneous vertebroplasty (PVP) Forensic Sci Int, pp.35-43, 2005. ,
DOI : 10.1016/j.forsciint.2004.06.010
Incidence of subsequent vertebral body fractures after vertebroplasty, Journal of Clinical Neuroscience, vol.21, issue.8, pp.1292-1299, 2014. ,
DOI : 10.1016/j.jocn.2013.12.022
Vertebroplasty and kyphoplasty: a comparative review of efficacy and adverse events, Current Reviews in Musculoskeletal Medicine, vol.18, issue.Suppl 2, pp.17-23, 2008. ,
DOI : 10.1007/s12178-007-9013-0
Management of Bone Metastases in Patients with Castration-Resistant Prostate Cancer, Urologia Internationalis, vol.92, issue.4, pp.377-86, 2014. ,
DOI : 10.1159/000358258
Skeletal metastases ??? The role of the orthopaedic and spinal surgeon, Surgical Oncology, vol.21, issue.3, pp.216-238, 2012. ,
DOI : 10.1016/j.suronc.2012.04.001
Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: Results from a randomised multicentre trial, Radiotherapy and Oncology, vol.91, issue.2, pp.261-267, 2009. ,
DOI : 10.1016/j.radonc.2009.02.014
Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases, JNCI Journal of the National Cancer Institute, vol.97, issue.11, pp.798-804, 2005. ,
DOI : 10.1093/jnci/dji139
Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30Gy in 10 fractions compared with 8Gy in single fraction, Radiotherapy and Oncology, vol.89, issue.2, pp.150-155, 2008. ,
DOI : 10.1016/j.radonc.2008.05.018
Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement., Radiology, vol.199, issue.1, pp.241-248, 1996. ,
DOI : 10.1148/radiology.199.1.8633152
Percutaneous injection of orthopedic cement in metastatic vertebral lesions, N Engl J Med Jul, vol.13321, issue.2, p.121, 1989. ,
Vertebroplasty in the treatment of vertebral tumors: postprocedural outcome and quality of life, European Spine Journal, vol.12, issue.4, pp.356-60, 2003. ,
DOI : 10.1007/s00586-003-0525-z
Supportive care aspects of vertebroplasty in patients with cancer. Support Cancer Ther, pp.98-104, 2005. ,
Percutaneous polymethylmethacrylate vertebroplasty in the treatment of pain induced by metastatic spine tumor, Surgical Neurology, vol.70, issue.1, pp.178-83, 2008. ,
DOI : 10.1016/j.surneu.2008.08.078
CT Fluoroscopy???guided Percutaneous Vertebroplasty for the Treatment of Osteolytic Breast Cancer Metastases: Results in 62 Sessions with 86 Vertebrae Treated, Journal of Vascular and Interventional Radiology, vol.19, issue.11, pp.1596-606, 2008. ,
DOI : 10.1016/j.jvir.2008.08.014
In Vivo Temperature Profile of Intervertebral Discs and Vertebral Endplates During Vertebroplasty, Spine, vol.31, issue.15, pp.1674-1682, 2006. ,
DOI : 10.1097/01.brs.0000224193.52587.d8
Osteoblastic and mixed spinal metastases: evaluation of the analgesic efficacy of percutaneous vertebroplasty, Am J Neuroradiol, vol.28, issue.3, pp.570-574, 2007. ,
Pelvic fractures following irradiation of endometrial and vaginal cancers???a case series and review of literature, Radiotherapy and Oncology, vol.56, issue.1, pp.23-31, 2000. ,
DOI : 10.1016/S0167-8140(00)00178-X
Insufficiency Fractures After Pelvic Radiotherapy in Patients With Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.77, issue.3, pp.818-841, 2010. ,
DOI : 10.1016/j.ijrobp.2009.05.059
Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer, Journal of Clinical Oncology, vol.30, issue.15, pp.1864-70, 2012. ,
DOI : 10.1200/JCO.2011.38.3745
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer, European Urology, vol.70, issue.3, 2016. ,
DOI : 10.1016/j.eururo.2016.02.035
Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy, Cancer Management and Research, 2014. ,
DOI : 10.2147/CMAR.S74116
Aggressive Variants of Castration-? Resistant Prostate Cancer. Clin Cancer Res, pp.2846-50, 2014. ,
Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic, Surg Neurol Int, vol.7, pp.361-366, 2016. ,
Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities, Nature Reviews Cancer, vol.2, issue.8, pp.584-93, 2002. ,
DOI : 10.1038/nrc867
Platinum-?Based Chemotherapy for Variant Castrate-?Resistant Prostate Cancer. Clin Cancer Res, pp.3621-3651, 2013. ,
DOI : 10.1158/1078-0432.ccr-12-3791
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699964